Developmental Funds

发展基金

• 批准号: 10580695
• 负责人: STEVEN K. LIBUTTI
• 金额: $ 36.85万
• 依托单位: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10580695
• 关键词: Achievement; Applications Grants; Area; Award; Basic Science; Bioinformatics; Cancer Center Support Grant; Cancer Institute of New Jersey; Catchment Area; Categories; Chemistry; Clinical Research; Collaborations; Computational Biology; Critiques; Data; Development; Disparity; Evaluation; Evolution; Faculty; Faculty Recruitment; Fostering; Funding; Genomics; Goals; Grant; Growth; Immunologic Monitoring; Immunology; Immunooncology; Immunotherapy; Individual; Institution; Investments; Laboratories; Leadership; Medical Oncology; Methodology; Molecular Epidemiology; Monitor; Neuroendocrine Tumors; Peer Review; Peer Review Grants; Philanthropic Fund; Pilot Projects; Population Research; Population Sciences; Process; Protocols documentation; Recording of previous events; Research; Research Personnel; Research Support; Resource Sharing; Resources; Strategic Planning; Surgical Oncology; Systems Biology; Technical Expertise; Tobacco; Universities; Vision; cancer pharmacology; career; cost; engineered T cells; innovation; instrumentation; member; metabolomics; novel; precision medicine; programs; recruit; research study; screening; small molecule

DEVELOPMENTAL FUNDS PROJECT SUMMARY/ABSTRACT CCSG developmental funds leveraged additional institutional support and provided an exceptionally strong return on investment. The $350,000 CCSG support of the New Investigator Award Program was supplemented by $80,000 of institutional/philanthropic funds, allocated to eight new faculty recruits, and generated a total of $9 million (total costs) in grant support. The $1.2 million CCSG support of the Pilot Project Program was supplemented by $1.5 million of institutional/philanthropic funds, generating $17.8 million (total costs) in grant support. The grand total of $26.8 million return on investment (ROI) includes over $26.6 million in peer reviewed grant support, and represents a 17.5-fold ROI of CCSG funds invested for New Investigator Awards and Pilot Projects. CCSG developmental funds further enabled shared resource evolution. The Metabolomics shared resource has matured to an established shared resource that offers unique technical expertise and ease-of-access to state-of-the-art instrumentation and current protocols that are not available in most individual investigator laboratories; this resource continues to fuel collaborative research with Princeton University and over a recent twelve-month period, served 19 investigators (17 of whom are CINJ members) across three CINJ programs. Given the continued substantial growth of the CINJ research enterprise, and the successful use of developmental funds in the current project period, we request $425,000 per year to be used in three categories: 1) recruitment of investigators in areas of strategic priority for CINJ (New Investigator Award program), 2) development of new shared resources in Immune Monitoring (responding to the Director’s initiative in Immune Oncology) and Small Molecule Screening (critical to all Basic programs and specifically responsive to a 2011 critique of the Cancer Pharmacology Program), and 3) pilot awards (Pilot Project program) to promote novel, collaborative research aligned with strategic priorities.

发展基金 项目概要/摘要 CCSG 发展基金利用了额外的机构支持，并提供了异常强大的支持 投资回报。 CCSG 对新研究者奖励计划的 350,000 美元支持 补充 80,000 美元的机构/慈善资金，分配给八名新聘教员，以及 总共产生了 900 万美元（总成本）的赠款支持。 CCSG 对试点项目的 120 万美元支持 项目计划由 150 万美元的机构/慈善基金补充，产生 17.8 美元 百万（总费用）的赠款支持。总计 2680 万美元的投资回报 (ROI) 包括 超过 2660 万美元的同行评审赠款支持，代表 CCSG 资金投资回报率的 17.5 倍 新研究者奖和试点项目。 CCSG 发展基金进一步促进了共享资源的发展。代谢组学共享资源 已成熟为一种既定的共享资源，可提供独特的技术专长和易于访问 大多数个人研究者都无法使用最先进的仪器和当前协议 实验室；该资源继续推动与普林斯顿大学的合作研究，并且在最近的一项研究中 在 12 个月的时间里，为三个 CINJ 项目的 19 名研究人员（其中 17 名是 CINJ 成员）提供服务。 鉴于 CINJ 研究事业的持续大幅增长，以及 在当前项目期间，我们请求每年 425,000 美元用于三个项目 类别： 1) CINJ 战略重点领域招募研究者（新研究者奖 计划），2）开发免疫监测方面的新共享资源（响应主任的 免疫肿瘤学倡议）和小分子筛选（对所有基础计划至关重要，特别是 回应 2011 年对癌症药理学计划的批评），以及 3）试点奖项（试点项目 计划），以促进与战略重点相一致的新颖的合作研究。